The biotech giant signed a commercial agreement with bioelectronics company Innervia, and the two will work collaboratively on vagus nerve stimulating technologies. 

More manufacturers are contributing their analytical data to an excipient database to pool knowledge on the risk posed by excipients that may cause drugs to exceed acceptable PDE levels under ICH Q3D.

UK engineering firm Dyson, best known for its vacuum cleaners, fans and hand driers, plans to make 10,000 specially designed ventilators under a UK government contract.

One of the most controversial, and potentially impactful, questions in medical device development today is how to better prevent late events, especially late stent-thrombosis, in coronary stent patients. The two leading answers to this question are a completely bioresorbable drug-eluting stent and a metal drug-eluting stent with a bioresorbable polymer, but there may be even more ideas on the horizon. One of the leading experts in the field and a cardiologist with experience with most of these new technologies, Robert Byrne of Deutsches Herzzentrum in Munich, recently talked to Medtech Insight about the questions that still need to be answered in this field and how it can move forward.